- Thinly traded nano cap Cardiome (CRME +3%) perks up on almost 2 1/2 times normal volume, albeit on turnover of only 90K shares, on the heels of its announcement that its has launched XYDALBA (dalbavacin) in France after receiving authorization from the French Transparency Pricing Commission. It is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
- SVP Commercial Hugues Sachot says, "We are extremely pleased with the progress we've made to date in launching XYDALBA across our licensed territories in Germany, the UK and now France. We've expanded our resources and commercial infrastructure across our European direct sales markets in support of a successful launch and our efforts are paying off by launching on schedule and building excitement around this product within the infectious disease community."